BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 21926451)

  • 1. [Harm reduction strategy in tobacco control].
    Gorini G
    Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No sisyphean task: how the FDA can regulate electronic cigarettes.
    Paradise J
    Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching.
    Hatsukami DK; Severson H; Anderson A; Vogel RI; Jensen J; Broadbent B; Murphy SE; Carmella S; Hecht SS
    Tob Control; 2016 May; 25(3):267-74. PubMed ID: 25991608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harm reduction policies for tobacco users.
    Gartner C; Hall W
    Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical laboratory evaluation of potential reduced exposure products for smokers.
    Breland AB; Kleykamp BA; Eissenberg T
    Nicotine Tob Res; 2006 Dec; 8(6):727-38. PubMed ID: 17132520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging nicotine delivery products. Implications for public health.
    Benowitz NL
    Ann Am Thorac Soc; 2014 Feb; 11(2):231-5. PubMed ID: 24575992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.
    Kozlowski LT; Abrams DB
    BMC Public Health; 2016 May; 16():432. PubMed ID: 27221096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
    Mendoza-Baumgart MI; Tulunay OE; Hecht SS; Zhang Y; Murphy S; Le C; Jensen J; Hatsukami DK
    Nicotine Tob Res; 2007 Dec; 9(12):1309-23. PubMed ID: 18058349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobacco, nicotine and harm reduction.
    Le Houezec J; McNeill A; Britton J
    Drug Alcohol Rev; 2011 Mar; 30(2):119-23. PubMed ID: 21375611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products.
    Hatsukami DK; Lemmonds C; Zhang Y; Murphy SE; Le C; Carmella SG; Hecht SS
    J Natl Cancer Inst; 2004 Jun; 96(11):844-52. PubMed ID: 15173268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health.
    Bates C; Fagerström K; Jarvis MJ; Kunze M; McNeill A; Ramström L
    Tob Control; 2003 Dec; 12(4):360-7. PubMed ID: 14660767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
    Gray JN; Breland AB; Weaver M; Eissenberg T
    Nicotine Tob Res; 2008 Sep; 10(9):1441-8. PubMed ID: 19023835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study.
    Goniewicz ML; Gawron M; Smith DM; Peng M; Jacob P; Benowitz NL
    Nicotine Tob Res; 2017 Feb; 19(2):160-167. PubMed ID: 27613896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
    Cobb CO; Weaver MF; Eissenberg T
    Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.
    Kotlyar M; Hertsgaard LA; Lindgren BR; Jensen JA; Carmella SG; Stepanov I; Murphy SE; Hecht SS; Hatsukami DK
    Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):91-100. PubMed ID: 21068204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of reduced-risk nicotine-delivery products on smoking prevalence and cigarette sales: an observational study.
    Pesola F; Phillips-Waller A; Beard E; Shahab L; Sweanor D; Jarvis M; Hajek P
    Public Health Res (Southampt); 2023 Sep; 11(7):1-39. PubMed ID: 37795840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction?
    Frost-Pineda K; Appleton S; Fisher M; Fox K; Gaworski CL
    Nicotine Tob Res; 2010 Nov; 12(11):1055-67. PubMed ID: 20847148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smokeless tobacco: a gateway to smoking or a way away from smoking.
    Melikian AA; Hoffmann D
    Biomarkers; 2009 Jul; 14 Suppl 1():85-9. PubMed ID: 19604066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Snuffing out cigarette sales and the smoking deaths epidemic.
    Laugesen M
    N Z Med J; 2007 Jun; 120(1256):U2587. PubMed ID: 17589555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.